- Home
- SRZN vs MNPR Comparison
SRZN vs MNPR Comparison
Compare SRZN & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | MNPR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | 44 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.9M | 368.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SRZN | MNPR |
|---|---|---|
| Price | $28.66 | $53.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $38.00 | ★ $107.00 |
| AVG Volume (30 Days) | 115.4K | ★ 168.5K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $75.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.11 | $28.40 |
| 52 Week High | $33.96 | $105.00 |
Technical Indicators
Market Signals| Indicator | SRZN | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 39.70 |
| Support Level | $23.95 | $50.77 |
| Resistance Level | $29.18 | $60.67 |
| Average True Range (ATR) | 2.42 | 3.03 |
| MACD | -0.05 | -0.32 |
| Stochastic Oscillator | 38.27 | 25.60 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.